Solid Tumor Clinical Trials

104 studies are recruiting for solid tumor in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

   The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   Sarah Cannon Research Institute, Denver, Colorado

   Locations

   2 in total

   Run by

   Rise Therapeutics LLC

   See if you can join NCT06398418 on ClinicalTrials.gov

2. Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors

   To evaluate the safety and preliminary efficacy of NP-101 in patients with solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06563375 on ClinicalTrials.gov

3. NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

   Background: All childhood cancers are rare, but some are called very rare. Very rare cancers are diagnosed in 2 or fewer out of 1 million people each year. Researchers want to gather data so they can learn more about these very rare cancers. They hope to use the data to develop future treatments. O…

   Stage

   Not phased

   Ages

   0 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07489378 on ClinicalTrials.gov

4. Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

   The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with soma…

   Stage

   Phase 1

   Ages

   2 to 18

   Site

   UCSF Benioff Children's Hospital, San Francisco, California

   Locations

   6 in total

   Run by

   ITM Solucin GmbH

   See if you can join NCT06441331 on ClinicalTrials.gov

5. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   20 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

6. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Banner Health- MD Anderson Cancer Center, Gilbert, Arizona

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

7. Dabrafenib and/or Trametinib Rollover Study

   This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by…

   Stage

   Phase 4

   Ages

   18 to 100

   Site

   Novartis Investigative Site, Toronto, Ontario

   Locations

   34 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT03340506 on ClinicalTrials.gov

8. Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

   The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the stud…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Hartford Healthcare (Data Collection), Hartford, Connecticut

   Locations

   10 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT04165772 on ClinicalTrials.gov

9. Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

   The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Facility, Phoenix, Arizona

   Locations

   14 in total

   Run by

   RayzeBio, Inc.

   See if you can join NCT07165132 on ClinicalTrials.gov

10. A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

    This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    28 in total

    Run by

    BeOne Medicines

    See if you can join NCT05981703 on ClinicalTrials.gov

11. DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer

    The purpose of this study is to improve ways of providing mental health support to Spanish-speaking Latino participants who have cancer and experience depression, insomnia, and fatigue. Investigators will test a special mental health intervention called DESCANSO/REST (Depresión/Depressed Mood, Cans…

    Stage

    Not phased

    Ages

    21 to 100

    Site

    Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07225088 on ClinicalTrials.gov

12. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

    AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC/Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    7 in total

    Run by

    Angiex, Inc.

    See if you can join NCT06440005 on ClinicalTrials.gov

13. Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

    The objective of this study is to assess the safety, efficacy, and pharmacokinetics of SA53-OS in adult participants with refractory solid tumors. The study is comprised of 2 parts: Part 1 called dose escalation, and Part 2a called dose expansion. This study starts with Part 1 where participants wh…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Gabrail Cancer Center, Canton, Ohio

    Locations

    3 in total

    Run by

    Lamassu Bio Inc

    See if you can join NCT06578624 on ClinicalTrials.gov

14. Psychotherapy Intervention for Latinos With Advanced Cancer

    The purpose of this study is to adapt a counseling intervention called Meaning Centered Psychotherapy to make it culturally relevant for Latinos. Cancer affects patients and their loved ones. Latinos often experience greater challenges due to the cancer. However, few studies and interventions focus…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    4 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04015609 on ClinicalTrials.gov

15. Psychotherapy Intervention for Latinos With Adv Cancer

    The purpose of this study is to adapt a counseling intervention called Meaning Centered Psychotherapy to make it culturally relevant for Latinos. Cancer affects patients and their loved ones. Latinos often experience greater challenges due to the cancer. However, few studies and interventions focus…

    Stage

    Not phased

    Ages

    18 and older

    Site

    MSK at Ralph Lauren, New York, New York

    Locations

    4 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04537936 on ClinicalTrials.gov

16. A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors

    The goal of this clinical study is to learn more about the study drug GS-1206, including its safety, tolerability, and antitumor activity in adult participants with solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest, LLC, Grand Rapids, Michigan

    Locations

    4 in total

    Run by

    Gilead Sciences

    See if you can join NCT07703878 on ClinicalTrials.gov

17. Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

    The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treating patients with advanced solid tumors that have come back or are not improving after receiving other drugs that are commonly used for their…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    13 in total

    Run by

    ImmunoGenesis

    See if you can join NCT06014502 on ClinicalTrials.gov

18. Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

    Background: Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small percentage of these tumors are familial. Researchers want to study these changes in biological samples from people with rare tumors in order t…

    Stage

    Not phased

    Ages

    0 and older

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Locations

    3 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT03739827 on ClinicalTrials.gov

19. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

    This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic, Phoenix, Arizona

    Locations

    25 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT05245500 on ClinicalTrials.gov

20. PRE-ISPY Phase I/II Oncology Platform Program

    PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama

    Locations

    10 in total

    Run by

    QuantumLeap Healthcare Collaborative

    See if you can join NCT05868226 on ClinicalTrials.gov

21. Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

    An open-label, Phase Ib dose escalation and dose expansion clinical trial evaluating the safety and efficacy of CBP-1019 combinations in patients with solid tumors of epithelial origin.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06576037 on ClinicalTrials.gov

22. A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

    This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UC San Diego Moores Cancer Center, La Jolla, California

    Locations

    42 in total

    Run by

    Genentech, Inc.

    See if you can join NCT06619587 on ClinicalTrials.gov

23. STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

    This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 [PD-1]) in advanced unresectable or metastatic tumors. The Phase 2…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    10 in total

    Run by

    STORM Therapeutics LTD

    See if you can join NCT06975293 on ClinicalTrials.gov

24. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic, Phoenix, Arizona

    Locations

    33 in total

    Run by

    Parabilis Medicines, Inc.

    See if you can join NCT05919264 on ClinicalTrials.gov

25. A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

    The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do

    Locations

    8 in total

    Run by

    Yuhan Corporation

    See if you can join NCT06616766 on ClinicalTrials.gov